TG Therapeutics Q3 EPS $0.73 May Not Be Comparable To $0.12 Estimate, Sales $165.81M May Not Be Comparable To $46.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics (NASDAQ:TGTX) reported Q3 earnings of $0.73 per share, beating the analyst consensus estimate of $0.12 by 508.33%. This is a 380.77% increase over losses of $(0.26) per share from the same period last year. The company also reported quarterly sales of $165.81 million, beating the analyst consensus estimate of $46.56 million by 256.13%. This is a 176.30K% increase over sales of $94.00 thousand the same period last year.
November 01, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics reported significantly higher Q3 earnings and sales than expected. This could lead to a positive short-term impact on the company's stock.
TG Therapeutics reported Q3 earnings and sales that significantly exceeded analyst estimates. This strong financial performance could increase investor confidence and demand for the stock, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100